Preparing commercialization of a “chronic alcoholic liver disease solution” in Chuncheon, Gangwon Province
AIDOT (CEO Jeong Jae-hoon) announced on the 26th that it received the Gangwon Technopark Director’s Award on December 16, 2022.
AIDOT was recognized for its contributions to strengthening the overseas competitiveness of Korea’s AI technology through the development of medical AI products, continued corporate growth and increased exports, expanding overseas markets, and promoting job creation by pursuing the establishment of a branch office in Gangwon Province.
AIDOT is currently carrying out a project under the research theme “Development and demonstration of an AI solution for predicting and diagnosing chronic alcoholic liver disease,” and it is preparing service commercialization by establishing a branch office in Chuncheon, Gangwon Province.
The solution can be used for early diagnosis based on patients’ stool samples, helping identify chronic alcoholic liver disease conditions such as fatty liver, hepatitis, cirrhosis, and suspected liver cancer. In existing testing methods for chronic alcoholic liver disease, invasive approaches could cause pain and side effects, while non-invasive approaches using CT or MRI also have limitations, including a cost burden of up to KRW 500,000, long testing times, and low sensitivity and specificity compared to liver tissue biopsy. However, AIDOT’s AI solution for predicting and diagnosing chronic alcoholic liver disease does not require a liver tissue biopsy, enabling diagnosis without pain, and it allows hospitals ranging from primary to tertiary care to diagnose the disease simply without additional tests such as CT or MRI.
An AIDOT representative said, “By using AI technology to predict chronic alcoholic liver disease through a non-invasive test (a stool test), we aimed to develop an innovative product that is more advantageous than existing methods in terms of safety, reliability, and cost.”
The representative added, “To commercialize this service, we will begin commercialization in the form of providing large-intestine microbial information, and we plan to continue participating in overseas exhibitions to identify buyers and proceed with commercialization overseas as well,” and said, “There is also demand for this business among our already established overseas clients, so we expect full-scale service provision to be possible once development is completed.”
Meanwhile, AIDOT completed regulatory registration with Vietnam’s Ministry of Health on December 6 for its cervical cancer screening system “Cerviray.” In addition, its stroke pre-screening solution “SONO dot AI” and its real-time AI gastroscopy solution “GIGA dot AI” received MFDS clinical trial plan approvals, and the company is also accelerating ongoing commercialization of its product portfolio aimed at overseas market expansion.
About AIDOT
Since its founding in June 2014, AIDOT has been recognized for its technological capabilities, including being selected for KIC China and various government projects. It developed the AI-based cervical cancer interpretation system “Cerviray A.I.” and is expanding into global markets centered on Southeast Asia. It also co-developed an AI-based interpretation system combining carotid ultrasound and genomic information with the Department of Neurosurgery at Hallym University Chuncheon Sacred Heart Hospital, and it has completed development of an AI diagnostic system for gastroenterology integrating gastroscopy, capsule endoscopy, and colonoscopy.
Website: aidot.ai
Published: December 26, 2022 / Newswire
